Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Allegro Begins Vitreomacular Traction Trial | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Allegro Begins Vitreomacular Traction Trial

Tests Integrin Peptide Therapy in VMT

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Allegro Ophthalmics has begun a Phase II study of ALG-1001 in patients with vitreomacular traction (VMT). ALG-1001 is a first-in-class Integrin Peptide Therapy targeting integrins, which play a key role in cell signaling and regulating cellular shape, motility, and the cell cycle.

The study is a placebo-controlled, randomized, double-masked, dose-ranging trial to evaluate the safety and efficacy of intravitreal injections of ALG-1001 in patients with VMT. Patients are currently being enrolled at multiple sites outside the U.S., with the primary efficacy endpoint of release of VMT being determined by optical coherence tomography (OCT) images read by Duke Reading Center. Secondary endpoints include the observation of non-surgical closure of full thickness macular holes, BCVA improvement over baseline, and forgone need for pars plana vitrectomy.

ALG-1001 approaches multiple indications by collectively turning off the production, reducing the leakage, and inhibiting the growth of aberrant blood vessels. In addition to its anti-angiogenic effects, ALG-1001 targets the key integrin receptor site at the vitreoretinal interface to release the cellular adhesion between the vitreous and the retina. Accordingly, inducing this separation has the potential to resolve VMT.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics